ZipPrime Biotechnology

ZipPrime is a biotechnology company focused on developing advanced solutions for the capture, detection, and preservation of nucleic acid molecules, particularly rare and fragile circulating-free DNA (cfDNA). The company’s core technology utilizes proprietary magnetic particle-based primer structures that allow for the single-molecule tagging and enrichment of DNA fragments. Unlike standard isolation and purification methods that often result in sample loss, ZipPrime’s workflow aims to improve the accuracy and reproducibility of clinical diagnostics. By enabling the creation of reusable cfDNA biomarker libraries, the platform supports downstream applications such as PCR-based protocols, microarrays, and Next-Generation Sequencing (NGS).

These innovations are designed to support early disease detection and clinical research, including applications in liquid biopsy for cancer diagnostics. By preventing the degradation of sensitive biomarkers, ZipPrime provides researchers and clinicians with a standardized, high-efficiency pre-analytical workflow. The company has also applied its nucleic acid handling expertise to develop diagnostic tools for infectious diseases, such as SARS-CoV-2 sampling and detection kits. With a background in molecular biology, ZipPrime’s R&D efforts have been recognized through grants and international partnerships, facilitating the commercialization of its technologies for global healthcare and diagnostic markets.